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AG-205 FOR THE TREATMENT OF BREAST
CANCER
SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted via EFS-Web and is hereby incorporated
by reference in its entirety. Said ACSII copy, created on Jun.
28, 2010, is named 10407260.txt and is 2,846 bytes in size.
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TECHNICAL FIELD
Compositions, methods, and combination therapies for
the treatment of cancers, including breast, colon, prostate,
melanomas, lung cancer, and metastatic disease, are pro
vided. Specifically, compositions comprising small mol
ecule ligands to Pgrmc1 are disclosed for use in treating and
inhibiting tumor growth and progression and inhibition of
metastases. The compositions and methods using these
ligands can be used alone or in combination with other
cancer treatment modalities.

15

20

BACKGROUND OF THE INVENTION
Cancer is one of the leading causes of death in the United
States. The growth and spread of many cancers is driven by
genes that are specifically activated in tumors. In many
cases, these genes encode proteins involved in metabolism
and signaling. Pgrmcl (progesterone receptor membrane
component 1) is a low molecular weight (approximately 25
kDa) protein that was originally thought to be a progesterone
receptor. However, it has been demonstrated that Pgrmcl
does not contain any homology to steroid receptors, but
instead has homology to cytochrome bs- Pgrmcl binds to
heme and has reducing activity, as the cytochrome proteins
do.
Pgrmcl is over-expressed in multiple types of cancer,
including breast, thyroid, colon, ovary and lung cancer.
Accordingly, Pgrmcl has great potential as a biomarker. In
breast cancer, Pgrmcl phosphorylation corresponds with
estrogen receptor status, and Pgrmcl levels correlate with
tumor grade in ovarian cancer. Pgrmc1 is also part of a gene
signature that predicts hypoxia in breast cancer. Pgrmcl is
also induced during dioxin-induced tumorigenesis and is
part of a six gene signature associated with non-genotoxic
carcinogens.
These findings are important because they indicate that
Pgrmcl is induced during tumor formation and is up
regulated in tumors in the clinic. One important function of
Pgrmcl in cancer is in chemotherapy resistance. The yeast
Pgrmcl homologue, Dapl (damage-associated protein), was
identified through its role in resistance to chemotherapy. In
cancer cells, Pgrmcl regulates survival in response to che
motherapeutic drugs, both in breast and ovarian cancer cells.
Like cytochrome proteins, Pgrmcl binds to heme and to
P450 proteins, a large class of proteins that are important in
drug metabolism, hormone synthesis and metabolism, and
lipid synthesis. Pgrmcl also binds to the cholesterol regu
lators Insig (insulin-induced gene) and Scap (sterol regulatory element binding protein cleavage activating protein),
and to the RNA binding protein PAIR-BPI (plasminogen
activator inhibitor 1 mRNA binding protein), although its
biological roles in these interactions is unclear. Indeed,
Pgrmcl does not regulate cholesterol synthesis in cancer
cells and has a minimal effect on P450 activity. In contrast,
Pgrmcl has an important role in cell signaling.
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Multiple studies have indicated a role for Pgrmcl in cell
signaling. The Pgrmcl sequence has binding sites for SH2
and SH3 domain-containing proteins and consensus phos
phorylation sites for tyrosine kinases. Our laboratory has
also shown a more direct role for Pgrmcl in signaling. When
damaged, breast cancer cells suppress death by sustaining
signaling through multiple protein kinases, including the
serine-threonine kinase Akt, and Pgrmcl promotes Akt
activation. This work was subsequently verified by another
group from Germany. Akt is activated by multiple pathways,
including the stimulation of receptor tyrosine kinases. This
led us to determine the extent to which Pgrmcl regulates
receptor tyrosine kinases in cancer cells, and we have found
that Pgrmcl binds to receptor tyrosine kinases and stabilizes
them at the plasma membrane.
Tyrosine kinases span the cell membrane and transmit
signals from extracellular polypeptide hormones. Activation
of the epidermal growth factor receptor (EGFR) signaling
pathway has been linked to increased proliferation, angiogenesis, metastasis and decreased apoptosis (Ritter et al.,
(2003) Semin Oneal, 30:3-11). The earliest studies with
EGFR involved an activated form of the receptor expressed
from transforming viruses (De Larco et al., (1980) J Biol
Chem, 255:3685-3690), and EGFR is up-regulated in a
variety of tumors, including colorectal cancer (72-82%),
head and neck cancer (95-100%), breast cancer (14-91%)
and renal cell cancer (59-90% (Saloman et al., (1995) Crit
Rev Oneal Hematol, 19:183-232). Furthermore, EGFR and
HER2/neu over-expression are associated with a poor prognosis in multiple tumor types (Brabender et al., (2001) Clin
Cancer Res., 7:1850-1855).
EGFR is inhibited by a growing number of drugs, includ
ing the antibody fragments cetuximab, matuzumab, nimo
tuzumab, zalutumumab and panitumumab and the small
molecule inhibitors erlotinib (Tarceva/OSI-774) and gefi
tinib (Ono et al., (2006) Clin Cancer Res, 12:7242-7251;
Bareschino et al., (2007) Ann Oneal, 18 Suppl 6:vi35-41).
EGFR inhibitors have promise for treating cancer, but there
effectiveness has been limited clinically. EGFR inhibitors
such as erlotinib are effective only in a subset of patients that
express mutated forms of the receptor. The most prominent
group of patients with these mutations is females that have
never smoked, leaving many patients with few therapeutic
options. A method of inhibiting the progression of cancers is
needed, which utilizes small molecule ligands to Pgrmcl.
SUMMARY OF THE INVENTION

50

55

60

65

One aspect of the present invention provides a method for
inhibiting tumor growth and/or metastatic progression and/
or development of metastases comprising administering a
ligand to Pgrmcl to a subject in need thereof in an amount
sufficient to inhibit tumor growth and/or metastases. One
mechanism of action for the ligand is destabilizing EGFR at
the plasma membrane, and other target proteins may apply.
The ligand may be AG-205. The tumor may be any tumor,
including a solid tumor, such as a breast, colon, lung or
prostate cancer, a lenkemia, melanoma or a lymphoma. The
tumors may be primary lesions or metastatic lesions.
The subject may be administered AG-205 in an amount of
about 1 mg/kg subject weight to about 100 mg/kg subject
weight. The tumor may be any solid tumor, such as a breast
tumor, and the subject may thus be administered AG-205
after surgical excision of the tumor. The subject may be
further subjected to surgery, isolated limb perfusion,
regional chemotherapy infusion, systemic chemotherapy, or
immunotherapy or antisera to treat the tumor.
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Regional chemotherapy infusion or the systemic chemo
therapy may comprise at least one chemotherapeutic agent
selected from the group consisting of: dacarbazine, carmus
tine, lomustine, tauromustine, fotemustine, semustine, cis
platin, carboplatin, vincristine, vinblastine, vindesine, taxol,
dibromodulcitol, detorubicin, doxorubicin, cyclophosph
amide, etoposide, piritrexim, and interferon.
The metastases may be a metastasis to brain, lung, liver,
peritoneal cavity or bone. The tumor may be further treated
with one or more chemotherapeutic agents and/or radiotherapy.
A further aspect of the present invention provides a
combination therapy for inhibiting tumor growth and/or
metastatic progression and/or development of metastases
administering a ligand to Pgrmcl to a subject in need thereof
in an amount sufficient to inhibit tumor growth and/or
metastases, wherein the ligand destabilizes EGFR and a
chemotherapeutic, and further administering an immuno
therapeutic, and/or radiation therapy.
The ligand may be AG-205 or a derivative. The ligand
may be administered intravenously, intrathecally, or subcu
taneously to a subject in need thereof. AG-205 may be
administered in any appropriate amount, for example in
amount of about 1 mg/kg subject weight to about 100 mg/kg
subject weight. The ligand may be administered daily,
weekly, or monthly.
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BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows that Pgrmcl increases tumor growth in
mouse xenografts. A549 cells were infected with a lentivirus
derived from the pGIPZ plasmid (A549/con) or a lentivirus
containing pGIPZ expressing a short hairpin RNA targeting
Pgrmcl (A549/RNAi). Athymic nude mice were injected
with A549/con or A549/RNAi cells. (A) Western blot analy
sis revealed that Pgrmcl expression was inhibited in the
excised A549/RNAi tumors (upper panel, lane 2), while
ku70 was unchanged. (B) The excised tumor weight of
A549/con was 2.9-fold greater than A549/RNAi. The results
support a model in which Pgrmcl promotes in vivo tumor
growth. (C) A549/con cells efficiently colonized the lungs
after tail vein injection (upper panels, fluorescent image on
left and bright field on right), while A549/RNAi cells were
deficient in lung colonization (lower panels). The results
from part C were quantitated and are presented graphically
in panel D. (For all figures, *=s0.05; **=s0.01; and
***=s0.005.) These results show that Pgrmcl increases in
vivo tumor growth both as sub-cutaneous tumors and
extravasated nodes in the lung.
FIG. 2 shows that Pgrmcl regulates anchorage-indepen
dent growth and migration, two key activities of tumor cells.
(A) In a soft agar growth assay, which measures anchorage
independent growth, a box plot demonstrates increased
colony size in A549/con compared to A549/RNAi cells.
Range is indicated by a vertical line, while 95% confidence
intervals are indicated by boxes. (B) A549/con cells formed
robust colonies in soft agar (left panel), while the colonies
arising from A549/RNAi cells were significantly smaller
(right panel). In panel C, the migration of A549/con and
A549/RNAi cells were measured using the Boyden chamber
assay, demonstrating a significant (P=0.002) decrease in
migration in the absence of Pgrmcl. Each of the assays was
performed in triplicate and is representative of multiple
independent experiments.
FIG. 3 shows that Pgrmcl promotes proliferation in the
absence of serum in cancer cells. (A) Viability in A549/con
and A549/RNAi cells was measured by cell counting from
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days 1-7 after serum withdrawal. Solid lines represent
control cells, while Pgrmcl-inhibited cells are indicated by
a dashed line. Measurements were in triplicate, and the
results are representative of three separate experiments. (B)
The cell cycle profiles A549/con and A549/RNAi cells were
analyzed by FACS 24 hours after serum deprivation, and
there was a small but significant increase in the G 1 popula
tion in A549/RNAi cells and a corresponding decrease in S
and G/M populations. (C) Western blot showing the expres
sion of the inactive mutant Pgr-hbd (heme binding-deficient)
in cells infected with the Ad-Pgr-hbd adenovirus (lane 2),
but not in cells infected with the same dose of control
Ad-Lacz adenovirus (lane 1). (D) Viability in Ad-Lacz
(solid lines) and Ad-Pgr-hbd-infected cells (dashed lines),
measured by cell counting 1-7 days after infection in media
lacking serum. (E) Western blot demonstrating Pgrmcl
inhibition by siRNA transfection in MDA-MB-468 cells. (F)
Viability of MDA-MB-468 cells transfected with a control
siRNA (solid line) or Pgrmcl-targeting siRNA (dashed line).
Measurements were in triplicate, and the results are repre
sentative of triplicate repeats.
FIG. 4 shows that the AG-205 compound binds to Pgrmcl
and inhibits tumor cell viability. (A) Pgrmcl (SEQ ID NO:
7) shares homology with AtMAPR2 (SEQ ID NO: 8)
(underlined residues), which was the target for a screen for
small molecule ligands. The putative heme-binding Tyr106
and Tyr112 are indicated with black boxes. (B) The molecu
lar structure of AG-205 includes multiple aromatic compo
nents. (C) Spectroscopic scan of Pgrmcl with vehicle control compared with vehicle plus 50 OM AG-205. The
decrease in relative absorbance at 400 nm is consistent with
an AG-205-induced change in the spectral properties of
Pgrmcl-heme. The scan is representative of four separate
scans using different Pgrmcl protein preparations. The
lower scan is a comparison of purified Pgrmcl without and
with the vehicle control (DMSO). Panels D (A549 cells) and
E (MDA-MB-231 cells) are viability assays of cells main
tained in 0.1% serum (solid line) or 10% serum (dashed line)
and treated with increasing doses of AG-205. Percent viability was determined by cell counting, and "% viability" refers
to the cell number relative to the untreated control. The
results show a highly significant loss of viability after
AG-205 treatment when cells are grown in the absence of
serum growth factors.
FIG. 5 shows that a Pgrmcl ligand induces cell cycle
arrest in a Pgrmcl-dependent manner. (A) Graph of tripli
cate FACS analysis. AG-205-treated cells (right columns)
had a significant G 1 arrest and accumulation of sub-G 1 cells,
while S and G2/M-phase cells were depleted from the treated
population. (B) Protein expression was analyzed by western
blot for Pgrmcl (top) and ku70 (bottom). Cells were treated
with O (lanes 1), 2 (lanes 2), 10 (lanes 3) or 50 (lanes 4) µM
AG-205 for 24 hours. The results show that the Pgrmcl
ligand AG-205 increases Pgrmcl expression in A549 cells.
(C-D) The panels show western blots of phosphorylated
ERKl/2 (upper panels) and total ERKl/2 (lower panels) The
lanes in panel C are A549/con (lane 1), A549/RNAi (lane 2),
A549/LacZ (lane 3) and A549/PGR-hbd cells (lane 4) fol
lowing 48 hours serum starvation. The cells infected with
adenovirus were similar to those described in FIG. 3, panels
C and D. In panel D, A549 cells were treated with vehicle
(lane 1) or 20 µM AG-205 (lane 2) for 24 hours in serum-free
media. (E) A549/con (solid line) or A549/RNAi (dashed
line) cells were treated with increasing doses of AG-205 for
72 hours and viability was measured by counting, and "%
viability" refers to the cell number relative to the untreated
control. (F) Cells expressing Lacz (solid line) or the
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Pgrmcl-hbd heme binding-deficient mutant (dashed line),
were treated with increasing doses of AG-205. The Pgrmcl
inhibitor partially reversed the loss of viability characteristic
of Pgrmcl-hbd-expressing cells. Percent viability was deter
mined by cell counting, and "% viability" refers to the cell
number relative to the untreated control. For each experi
ment, the results are representative of experiments per
formed at least in duplicate.
FIG. 6 shows that Pgrmcl promotes EGFR inhibitor
sensitivity. (A) A549/con (solid line) or A549/RNAi (dashed
line) cells were maintained in media lacking serum and
treated with 2.5-10 µM of the EGFR inhibitor AG1478 for
96 hours. Percent viability was determined by cell counting,
and for all of the panels "% viability" refers to the cell
density relative to untreated cells. (B) AG1478 susceptibility
in Ad-Lacz and Ad-Pgr-hbd-infected A549 cells, measured
by MTT assay 4 days after infection in serum-free media
containing increasing doses of AG-1478. Solid lines repre
sent cells infected with the control Ad-Lacz, while Ad-Pgr
hbd-infected cells are indicated by a dashed line. (C) A549
cells were treated with vehicle (solid line) or 10 µM AG-205
(dashed line) plus increasing doses of erlotinib and counted.
(D) MDA-MB-231 breast cancer cells were treated with
AG-205 and erlotinib as described in panel C. Each of the
experiments is representative of experiments performed at
least in triplicate. The results indicate that increases in
proliferation in Pgrmcl-expressing cells are reversed by
EGFR inhibitors.
FIG. 7 shows that EGFR and Pgrmcl co-precipitate and
co-localize. (A) EGFR was precipitated with the antibody
IMC-C225 from serum-starved A549 cells and probed for
EGFR (top panel) or Pgrmcl (second panel). Lane 1 is a
control precipitation with an irrelevant antibody. (B) For the
inverse experiment, Pgrmcl was precipitated from A549
cells with pre-immune serum (PIS, lane 1) or an anti-Pgrmcl
antibody (a-Pgr, lane 2). EGFR was detected in the latter
reaction (lower panel). (C) EGFR was immuno-precipitated
from serum-starved A549/con (lane 1) or A549/RNAi (lane
2) cells. Immuno-precipitation reactions were probed for
EGFR (top) or Pgrmcl (bottom). (D) EGFR was immuno
precipitated with IMC-C225 from MDA-MB-231 breast
cancer cells, and precipitation reactions were analyzed by
western blot for EGFR (upper panel) or Pgrmcl (lower
panel). (E) The upper panels show fluorescence of Pgrmcl
GFP expressed in A549 cells and immunofluorescence for
EGFR, which was detected with a rhodamine-labelled sec
ondary antibody. The lower panel shows a merged image,
indicating that Pgrmcl and EGFR co-localize to an intrac
ellular region adjacent to the nuclear membrane. The bar
indicates 25 µm.
FIG. 8 shows that Pgrmcl increases EGFR levels in
MDA-MB-468 breast cancer cells. Panel A is a diagram
indicating the positions of the siRNA molecules targeting
Pgrmcl. Exons 1, 2 and 3 are indicated by "ex". MDA-MB468 cells were transfected with a control siRNA (siCON,
lanes 1 and 3) or two separate siRNAs targeting Pgrmcl
(siPGR and siPGR2, lanes 2 and 4, respectively). In panels
B-E and H-L, protein levels were analyzed by western blot
for EGFR (B), phospho-tyrosine (C), Pgrmcl (D) and ku70
(E), as a control for protein loading. Panels F-H show
western blot analyses for (F) IGF-lR, (G) c-Kit and (H) tfR.
In panels I and J, transcript levels were analyzed by reverse
transcriptase-PCR for EGFR (I) and Pgrmcl (J). The top
band indicates the gene of interest, while actin primers were
included in the same reaction as a control for cDNA loading.
The results show that Pgrmcl regulates EGFR protein levels
with little effect on EGFR transcription. In panels K-L,
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MDA-MB-468 cells were treated with increasing doses of
the Pgrmcl ligandAG-205. Protein expression was analyzed
by western blot for EGFR (K) and ku70 (L). Cells were
treated with O (lanes 1), 2 (lanes 2), 10 (lanes 3) or 50 (lanes
4) µM AG-205 for 24 hours in serum-free medium. In panels
M-N, A549 cells were treated with the same doses and
analyzed for EGFR (M) and ku70 (N). The results show that
the Pgrmcl ligand AG-205 decreases EGFR protein levels.
Expression analyses were repeated at least in duplicate
throughout.
DETAILED DESCRIPTION OF THE
INVENTION
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As used throughout the specification and the appended
claims, the terms listed below have the following meanings,
wherein "a" means one or more:
By "EGFR" is meant epidermal growth factor receptor.
By "RTK" is meant receptor tyrosine kinase.
By "Pgrmcl" is meant progesterone receptor membrane
component 1.
By the term "subject" or "patient" as used herein is meant
to include a mammal. The mammal can be a canine, feline,
primate, bovine, ovine, porcine, camelid, caprine, rodent, or
equine. Preferably the mammal is human.
The term "efficacy" as used herein refers to the effective
ness of a particular treatment regime. Efficacy can be
measured based on such characteristics (but not limited to
these) as inhibition of tumor growth, reduction of tumor
mass, reduction of metastatic lesions as assessed, for
example, by radiologic imaging, slowed tumor growth, lack
of detectable tumor associated antigens, and the like. Addi
tional methods of assessing tumor progression are discussed
herein and would be kuown to the treating and diagnosing
physicians.
By the phrases "pharmaceutically acceptable carrier" and
"pharmaceutically acceptable excipient" are intended to
mean any compound(s) used in forming a part of the
formulation that is intended to act merely as a carrier, i.e.,
not intended to have biological activity itself. The pharma
ceutically acceptable carrier or excipient is generally safe,
non-toxic, and neither biologically nor otherwise undesir
able. A pharmaceutically acceptable carrier or excipient as
used herein includes both one and more than one such carrier
or excipient.
The terms "treating", and "treatment", and the like are
used herein to generally mean obtaining a desired pharma
cological and physiological effect. More specifically, the
reagents described herein which are used to treat a subject
with a tumor and metastatic disease generally are provided
in a therapeutically effective amount to achieve any one or
more of the following: inhibited tumor growth, reduction in
tumor mass, loss of metastatic lesions, inhibited development of new metastatic lesions after treatment has started, or
reduction in tumor such that there is no detectable disease
(as assessed by e.g., radiologic imaging, biological fluid
analysis, cytogenetics, fluorescence in situ hybridization,
immunocytochemistry, colony assays, multiparameter flow
cytometry, or polymerase chain reaction). The term "treat
ment", as used herein, covers any treatment of a disease in
a mammal, particularly a human.
By "therapeutically effective amount" is meant an amount
of an agent, reagent, compound, composition, or combina
tion of reagents disclosed herein that when administered to
a mammal is sufficient to be effective against the tumor.
By the term "tumor" is meant to include both benign and
malignant growths or cancer. Thus, the term "cancer", unless
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otherwise stated, can include both benign and malignant
growths. Preferably, the tumor is malignant. The tumor can
be a solid tissue tumor such as a melanoma, or a soft tissue
tumor such as a lymphoma, a leukemia, or a bone cancer.
By the term "primary tumor" is meant the original neoplasm and not a metastatic lesion located in another tissue or
organ in the patient's body.
By the terms "metastatic disease", "metastases", and
"metastatic lesion" are meant a group of cells which have
migrated to a site distant relative to the primary tumor.
Receptor tyrosine kinases were among the first proto
oncogenes ever identified. Alterations in RTKs, such as
EGFR and HER2/neu, are associated with a variety of
cancers. RTK inhibitors such as herceptin, erlotinib and
iressa are currently among the most promising agents in
development for treating cancer, and they extend both
overall survival and disease-free progression in some
patients. RTK inhibitor treatments do not have the harsh side
effects associated with traditional chemotherapy. However,
patients do not respond uniformly to these RTK inhibitors,
and comprehensive genetic screening ofevery cancer patient
will likely be expensive and complex.
Pgrmc1 (progesterone receptor membrane component 1)
is a protein that is up-regulated in multiple types of cancer,
including breast, lung, colon and ovarian cancer. Pgrmcl
binds to heme and stimulates the activity of P450 proteins,
which catalyze many critical reactions in lipid and hormone
synthesis. It has been previously shown that Pgrmcl regu
lates protein kinase signaling downstream from EGFR, and
the role of Pgrmcl in activating EGFR has been investigated. Pgrmcl was inhibited in A549 human lung cancer
cells and MDA-MB-468 human breast cancer cells by a
combination ofsiRNA and shRNA expression directed from
a lentivirus. Pgrmcl inhibition caused a 4-25-fold decrease
in EGFR levels. This drop in EGFR was accompanied by a
27-40% decrease in proliferation in MDA-MB-468 and
A549 cells. Pgrmcl also caused a 2.9-fold drop in anchor
age-independent growth and 4.1-fold inhibited migration in
A549 cells. In both cell types, Pgrmcl inhibition had no
effect on EGFR transcription, indicating that the effect was
post-translational. Pgrmcl bound to caveolin, a membrane
protein that binds to cholesterol and receptor tyrosine
kinases. Finally, a Pgrmcl ligand de-stabilized EGFR and
induced cell death in multiple tumor cell lines.
Pgrmcl is a component of a hormone/drug receptor
complex that is over-expressed in tumors and stabilizes
RTKs. Furthermore, new Pgrmcl inhibitors de-stabilize
EGFR through a distinct mechanism from other agents and
could be used in combinations with multiple existing drugs.
This could provide a new therapeutic option in the clinic for
cancer patients that have developed resistance to currently
available drugs.
It has been found that Pgrmcl directly associates with
EGFR in lung and breast cancer cells, as well as in cells of
other cancer types. Inhibition of Pgrmcl causes EGFR
levels to diminish at the plasma membrane, likely due to
defective trafficking to the plasma membrane or increased
endocytosis from the plasma membrane. By stabilizing
EGFR at the plasma membrane, Pgrmcl increases the sen
sitivity of lung cancer cells to the EGFR inhibitor erlotinib,
underscoring the importance of Pgrmcl in EGFR function.
Furthermore, genetic inhibition of Pgrmcl de-stabilizes
EGFR in breast cancer cells expressing high levels ofEGFR,
suggesting multiple routes through which Pgrmcl affects
EGFR function.
The small molecule ligand of Pgrmcl, called AG-205,
was identified in 2005 using an in silica screen with the
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Pgrmcl homologue from the flowering plant Arabidopsis
thaliana. AG-205 was found to bind to At Pgrmcl, but no
subsequent research was conducted on the biochemical or
biological activity of AG-205. It was found that AG-205 is
toxic to multiple cancer cell lines from lung, breast, colon
and prostate tissues. Any cell line over-expressing Pgrmcl
may be targeted by AG-205, due to the role of Pgrmcl in
promoting cell signaling. Indeed, AG-205 is most active
when serum is absent, likely because cells are deprived of
super-physiological levels of growth factors and require
Pgrmcl for efficient survival signaling. AG-205 may be
limited by its solubility, and thus derivatives ofAG-205 are
included herein, as optimized for their enhanced solubility,
specificity and delivery.
Receptor Tyrosine Kinases as Cancer Therapeutic Targets
Receptor tyrosine kinases (RTKs) were originally discov
ered through their association with cancer. EGFR has been
identified as regulating RTK stability and activation.
EGFR (Erb-Bl) is part of a family of proteins that
includes Erb-B2/HER2/neu, Erb-B3/HER3 and ErbB4/
HER4. Activation of the EGFR signaling pathway has been
liuked to increased proliferation, angiogenesis, metastasis
and decreased apoptosis (Ritter et al., (2003) Semin Oneal
30(1 Suppl 1):3-11). At least five mitogenic growth factors
bind and activate EGFR: EGF, TGF-a, amphiregulin, hepa
rin-binding EGF and epiregulin. The earliest studies with
EGFR involved an activated form of the receptor expressed
from transforming viruses (De Larco et al., (1980) The
Journal ofBiological Chemistry 255(8):3685-3690; Down
ward et al., (1984) Nature 307(5951):521-527), and c-EGFR
and HER2/neu can transform NIH-3T3 cells (Di Fiore et al.
(1987) Cell 51(6):1063-1070). EGFR is up-regulated in a
variety of tumors, including colorectal cancer (72-82%),
head and neck cancer (95-100%), breast cancer (14-91%)
and renal cell cancer [59-90% (Salomon et al., (1995) Crit
Rev Oneal Hematol 19(3):183-232)]. Furthermore, EGFR
and HER2/neu over-expression are associated with a poor
prognosis in multiple tumor types [(Brabender et al., (2001)
Clin Cancer Res 7(7):1850-1855), reviewed in (Ono et al.,
(2006) Clin Cancer Res 12(24):7242-7251)]. EGFR is acti
vated by a number of mechanisms, including over-expression, amplification and activating mutations Sebastian et al.,
(2006) Biochim Biophys Acta 1766(1):120-139).
EGFR is inhibited by the drug erlotinib (Tarceva/OSI774), a quinazoline-based agent which associates with the
ATP binding region of EGFR (Bareschino et al., (2007) Ann
Oncol 18 Suppl 6:vi35-41). Erlotinib was approved by the
FDA in 2004 for the treatment of chemotherapy-resistant
advanced NSCLC following a 731 patient multicenter phase
III trial in which erlotinib significantly improved overall
survival and progression-free survival in NSCLC patients
after one or two chemotherapy regimens had failed.
One promising strategy with EGFR inhibitors appeared to
be combining them with other drugs. However, clinical trials
combining EGFR inhibitors with chemotherapy have not yet
been successful (Herbst et al., (2005) J Clin Oneal 23(25):
5892-5899). EGFR and Src inhibitors are a promising com
bination for head and neck cancer (Koppikar et al., (2008)
Clin Cancer Res 14(13):4284-4291). Thus, erlotinib and
other targeted therapeutics have promise for treating cancer,
but in clinical terms, the responses are far from complete.
One approach to more effective targeting of these inhibitors
is to design drug combinations that accommodate the regu
lation and trafficking of EGFR in lung cancer cells.
Another strategy is to identify patients with the greatest
potential of benefiting from EGFR inhibitors. Cell lines
exhibit markedly different responses to EGFR inhibitors
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(Ono et al., (2006) Clin Cancer Res 12(24):7242-7251), a
fact that probably reflects the cells' genetic backgrounds.
Where EGFR performs an essential function in proliferation
and survival, the drugs are highly effective. In other back
grounds, the benefits of the drugs are limited. Responsiveness to EGFR inhibitors is difficult to predict. Tumors
harboring EGFR activating mutations respond well to EGFR
inhibitors, but some tumors expressing mutant EGFR are
inhibitor-resistant (Reinmuth et al., (2006) Int J Cancer
119(4):727-734). In addition, some tumors with amplified
EGFR have increased sensitivity to EGFR inhibitors.
Recently, there has been increasing interest in blocking
RTK function by inhibiting their processing, and inhibitors
of glycosylation and chaperones are effective at disrupting
RTK function and drug resistance (Contessa et al., (2008)
Cancer Res 68(10):3803-3809).
Pgrmc 1 (progesterone receptor membrane component 1)
is a member of a multi-protein progesterone-binding com
plex (Meyer et al., (1996) Eur J Biochem 239(3):726-731),
and Pgrmcl has also been named Hpr6.6 [human membrane
progesterone receptor (Gerdes et al., (1998) Biol Chem
379(7):907-911)]. Pgrmcl does not bind directly to proges
terone (Min et al., (2005) Febs J 272(22):5832-5843) and
has no homology with steroid receptors (Mifsuf et al.,
(2002) Genome Biol 3(12):RESEARCH0068), nuclear or
membrane-associated. Instead, Pgrmcl resides in the endo
plasmic reticulum (Crudden et al., (2005) Tumour Biol
26(3):142-146), where it binds to various proteins impli
cated in lipid metabolism, including caveolin/Cavl, Insig-1
(insulin-induced gene), Scap (SREBP cleavage activating
protein) and P450 proteins (Bramley et al., (2002) Domest
Anim Endocrinol 23(1-2):3-12). These findings suggest a
model in which a multi-protein Pgrmcl complex responds to
changes in lipid and/or hormone levels and transports sig
naling proteins to the cell membrane.
The endogenous Pgrmcl ligand is heme (Crudden et al.
(2006) J Pharmacol Exp Ther 316(1):448-455). Pgrmcl
shares key structural motifs with cytochrome b5 (Mifsud
2002), a heme binding protein that activates cytochrome
P450 proteins Pharmacology & therapeutics 97(2):139152). Pgrmcl binds and activates P450 proteins (Hughes et
al., (2007) Cell Metab 5(2):143-149), which metabolize
drugs, hormones and lipids. Heme is also implicated in Cavl
function, because Cavl binds to several heme-containing
proteins, including heme oxygenase (Jung et al., (2003)
IUBMB Life 55(9):525-532) and NOS (Garcia-Cardena et
al., (1997) The Journal of biological chemistry 272(41):
25437-2544).
The heme binding site of Pgrmcl is predicted to be a
prominent groove at the center of the protein. Notably, all of
the residues that are known to be important in heme binding
cluster along one face of the protein. The Asp120 residue,
which is required for heme binding (Crudden et al., 2006),
is at the center of the groove. The Tyrl07 and Tyr113 sites
are required for heme binding and localize to the right of the
groove. Interestingly, the Tyrl13 site is a proposed phos
phorylation site for the Ab! tyrosine kinase (Cahill (2007) J
Steroid Biochem Mal Biol 105(1-5):16-36), but this phos
phorylation event has not been formally demonstrated.
Finally, the Tyr164 residue, which is analogous to the
Tyr138 of yeast, is required for heme binding and localizes
to the side of the heme-binding groove.
It has been shown that Pgrmcl stabilizes EGFR in human
cancer cells. This follows on earlier findings that Pgrmcl is
over-expressed in breast tumors and in cancer cell lines from
the colon, thyroid, lung, and cervix (Crudden et al., (2005)
Tumour Biol 26(3):142-146). In ovarian cancer, Pgrmcl
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expression increased in advanced stage tumors, and Pgrmcl
was homogeneously expressed within the tumors (Peluso et
al., (2008) J Clin Endocrinol Metab 93(5):1592-1599).
Microarray analyses have also detected Pgrmcl expression
in colon, lung, ovarian and breast tumors (Difilippantonio et
al., (2003) Eur J Cancer 39(13):1936-1947).
Yeast cells lacking the Pgrmcl homologue, Dapl, are
sensitive to DNA damage (Craven et al., (2007) J Biol Chem
282(50):36543-36551) due to a failure in a repair process.
Like Pgrmcl, Dapl binds to heme (Ghosh et al., (2005)
Biochemistry 44(50):16729-16736), and heme binding is
essential for damage resistance (Mallory et al., (2005) Mal
Cell Biol 25(5):1669-1679). Furthermore, exogenous heme
or over-expression of the heme synthetic pathway can over
come the requirement for Dapl in damage resistance J Biol
Chem 282(50):36543-36551).
Because of the role of Dapl in damage resistance,
whether Pgrmcl has an analogous function in cancer cells
was tested. Pgrmcl was inhibited by expression of a domi
nant-negative, heme binding-deficient mutant or by siRNA,
and either treatment sensitized breast cancer cells to the
chemotherapeutic drugs doxorubicin and camptothecin
(Crudden et al., (2006) J Pharmacol Exp Ther 316(1):448455). These drugs are inhibitors of topoisomerase II and
topoisomerase I, respectively. Peluso, et al. reported similar
results in ovarian cancer cells treated with cisplatin (Peluso
et al., 2008). Pgrmcl expression is induced by chemo
therapy (Crudden et al., 2006) and in mouse cells with short
telomeres (Franco et al., (2005) Carcinogenesis 26(9):16131626), which suffer chromosomal damage during senes
cence and crisis. These results suggest that Pgrmcl induc
tion is a consequence of DNA damage, and Pgrmc 1 plays a
role in suppressing damage-induced cell death in cancer
cells.
Ligands for the Pgrmcl Heme Binding Site
Pgrmcl is unusual because it has both the characteristics
of a cytochrome and a receptor, suggesting a regulatory
point in metabolism. Yoshitani, et al. identified a novel class
of Pgrmcl ligands by combining molecular modeling of the
Arabidopsis thaliana Pgrmcl structure with binding assays
using Pgrmcl immobolized on a Biocore chip ((2005)
Proteomics 5(6): 1472-1480). A. thaliana is structurally con
served with mammalian Pgrmcl in the heme-binding site,
and the two proteins have a similar overall structure. While
Yoshitani identified four Pgrmcl ligands and measured their
binding affinity, they performed only biochemical assays
and did not explore a physiological function for the ligands.
Pgrmcl ligands are predicted to bind to the heme-binding
crevice of Pgrmcl (Yoshitani et al., (2005) Proteomics
5(6):1472-1480), suggesting that the ligands could displace
heme from its binding site. Heme binding is critical for the
activity of Pgrmcl homologues (Hughes et al., (2007) Cell
Metab 5(2):143-149), suggesting that the Pgrmcl ligands
would act as Pgrmcl inhibitors. The present invention
provides a mechanism showing that these ligands inhibit
EGFR stability and induce cell death in cancer cells.
Receptor tyrosine kinases are among the most important
proteins in cancer, driving the growth, survival and spread of
tumor cells. A previously unknown step in RTK regulation
has been identified, in which a heme-binding steroid recep
tor component, Pgrmcl, stabilizes EGFR and promotes
proliferation, anchorage-independent growth and invasion.
It has previously been shown that Pgrmcl is over-expressed
in tumors (Crudden et al. (2005) Tumour Biol 26:142-6),
including breast tumors. Pgrmcl is induced by chemo
therapy (Mallory et al., (2005) Mal Pharmacol 68:1747-56)
and is implicated in chemotherapy resistance (Crudden et
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al., (2006) J Pharmacol Exp Ther 316:448-55). However,
many tumors express Pgrmcl prior to chemotherapy, sug
gesting a function for Pgrmcl other than drug resistance. In
fact, Pgrmcl activates Akt (Hand et al. (2003) J Cell
Biochem 90:534-47), a pro-survival signaling kinase, in
breast cancer cells. A novel Pgrmcl ligand has been iden
tified that de-stabilizes EGFR and triggers cell death.
Another potential mechanism through which Pgrmcl
might stabilize EGFR is via an interaction with the PAIR
BPl mRNA binding protein. The target of PAIR-BPI is the
PAil protein, which is associated with tumor invasion and
vascularization (Bajou et al. (1998) Nat Med 4:923-8).
However, in Pgrmcl-inhibited cells, no change in PAil
transcript levels was detected. This result does not support a
model in which Pgrmcl stabilizes EGFR by altering PAil
levels via binding to PAIR-BPI. However, the model that a
Pgrmcl-PAIR-BPl complex stabilizes EGFR via an inter
mediate other than PAil carmot be excluded.
Because the predicted structure of Pgrmcl contains a
well-defined ligand binding domain (Song et al., (2004) J
Biomol NMR 30:215-8), the ability of a novel Pgrmcl ligand
to inhibit Pgrmcl was tested. AG-205 inhibited EGFR
stability at micromolar levels, similar to the effect of Pgrmc1
inhibition by RNAi, and AG-205 induced cell death in
cancer cells. This is surprising, because siRNA for Pgrmcl
was not toxic. This suggests that other proteins related to
Pgrmcl, including Pgrmc2 (Gerdes et al. (1998) Biol Chem
379:907-11) and Neudesin/SPUF (Kimura et al., (2008) J
Biol Chem 283:4323-31), may compensate for the loss of
Pgrmcl following siRNA inhibition. Because these proteins
have a similar heme-binding domain to Pgrmcl, they likely
bind to AG-205. Alternately, AG-205 may bind to proteins
other than Pgrmc1 that are important in maintaining viability
in cancer cells.
The effect of a Pgrmcl ligand on EGFR levels and
viability was also tested. The AG-205 compound was iden
tified by Yoshitani, et al. ((2005) Proteomics 5(6):14721480), who used a two-step process that began with com
putational screening based on the NMR structure of an A.
thaliana Pgrmcl homologue, called AtMAPR2 (A. thaliana
membrane-associated progesterone receptor 2) or
At2g24940. Pgrmcl contains 64% identity with AtMAPR2
in two separate regions of the heme-binding domain, begin
ning with residues Ala90 and Thr151. The screen for
AtMAPR2 ligands began with modeling of the putative
heme-binding site of AtMAPR2. From the computational
screen, 69 compounds were selected for further testing with
purified AtMAPR2 using surface plasmon resonance. The
affinity characteristics of the top four candidates were then
tested individually. All of the four highest affinity ligands
had a similar structure, with aryl rings bridged by a short
backbone.
There are four aromatic ligands for the Arabidopsis
thaliana Pgrmcl homologue, AtMAPR2, which is highly
conserved with human Pgrmcl in the heme-I domain. One
of the AtMAPR2 ligands with the highest binding affinity is
called AG-205 and is an aromatic compound. Based on the
putative structure of Pgrmcl, the majority of the conserved
residues cluster in a pocket that is analogous to the
AtMAPR2 ligand binding site. Tyr106 and Tyr112 are
required for heme binding. The addition of AG-205 to
purified Pgrmcl caused a shift in absorbance at approxi
mately 400 nm, with a smaller shift at approximately 530
nm. The results suggest that AG-205 alters the spectroscopic
properties of the Pgrmcl-heme complex.
EGFR is one of the most prominent therapeutic targets in
cancer, and is inhibited clinically by the antibody fragment
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erbitux/cetuximab and by the small molecule inhibitors
erlotinib and gefitinib. However, the fraction of patients that
responds to erlotinib is somewhat limited, and there are
safety concerns with erlotinib as well (see the Food and
Drug Administration website Medwatch for Tarceva (ww
w.fda.gov/medwatch/safety/2008/safety08.htm#Tarceva)).
One of the curious features of AG-205 is that it is more
active against cell lines expressing wild-type EGFR than the
llE746-A750 mutant EGFR. In contrast, the llE746- A750
mutant is more sensitive to erlotinib than cells expressing
wild-type EGFR. Furukawa, et al. have shown that llE746A750 mutant EGFR in constitutively active and exhibits
deficient Cb! binding, ubiquitination and endocytosis (Furu
kawa et al., (2007) DNA Cell Biol 26: 178-85). Interestingly,
it was found that there is an intracellular pool of EGFR in the
early stages following AG-205 treatment in MDA-MB-468
cells. Thus, one possible model is that Pgrmcl sustains
EGFR at the cell membrane, and that llE746-A750 mutants
do not require Pgrmcl for their membrane localization.
In one aspect of the invention, the methods and compositions disclosed herein can be used to treat, inhibit or slow
the progression of malignancies. These malignancies can be
solid or soft tissue tumors. Soft tissue tumors, or liquid
tumors, include bone cancers, lymphomas, and leukemias.
Another aspect of the invention is to use the methods and
compositions to inhibit or prevent metastases or metastatic
progression.
Thus, an aspect of the invention is to treat tumors or
metastatic disease with a ligand to Pgrmcl. These ligands
can be used alone, in combination with each other, or in
combination with other cancer modalities, such as but not
limited to chemotherapy, surgery, radiotherapy, hyperther
mia, immunotherapy, hormone therapy, biologic therapy
(e.g., immune effector mechanisms resulting in cell destruc
tion, cytokines, immunotherapy, interferons, interleukin-2,
cancer vaccine therapy, and adoptive therapy), and drugs to
ameliorate the adverse side effects of such cancer modalities.
The term cancer embraces a collection of malignancies
with each cancer of each organ consisting of numerous
subsets. Typically, at the time of cancer diagnosis, "the
cancer" consists in fact of multiple subpopulations of cells
with diverse genetic, biochemical, immunologic, and bio
logic characteristics.
Preferred cancers to be treated by the present invention
include but are not limited to melanomas (e.g., cutaneous
melanoma, metastatic melanomas, and intraocular melano
mas), prostate cancer, lymphomas (e.g., cutaneous T-cell
lymphoma, mycosis fungicides, Hodgkin's and non-Hodg
kin's lymphomas, and primary central nervous system lymphomas), leukemias (e.g., pre-B cell acute lymphoblastic
leukemia, chronic and acute lymphocytic leukemia, chronic
and acute myelogenous leukemia, adult acute lymphoblastic
leukemia, mature B-cell acute lymphoblastic leukemia, pro
lymphocytic leukemia, hairy cell leukemia, and T-cell
chronic lymphocytic leukemia), and metastatic tumors
which exhibit these proteins on the cell surface. See Lynn D.
Wilson et al., "Cutaneous T-Cell Lymphomas," in C AN
CER: PRINCIPLES & PR ACTICE OF ONCOLOGY 22202232 (Vincent T. DeVita, Jr. et al., editors, 5th ed. 1997);
Bauk et al., 1999, J. Cutan. Pathol., 26(2): 65-71. For
example, the cancer may be lung cancer.
Once a tumor is diagnosed in a patient, the first question
is whether the tumor has progressed and spread to the
regional lymph nodes and to distant organs. In the end, most
cancer deaths result from metastases that are resistant to
conventional cancer therapies. Metastases can be located in
different organs and in different regions of the same organ,
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making complete eradication by surgery, radiation, drugs,
and/or biotherapy nearly impossible. Also contemplated for
treatment with the methods, combination therapies, and
compositions disclosed herein is the treatment of metastatic
cancer. Cancers typically begin their growth in only one
location in the tissue of origin. As the cancer progresses, the
cancer may migrate to a distal location in the patient. For
example, a cancer beginning in the prostate may mi grate to
the lung. Thus, if a primary tumor is given enough time to
go through these steps, it will form metastatic lesions at a
site or sites distant to the prim ary tumor. The reagents,
methods, and combination therapies disclosed inhibit or
prevent one or more of these steps in the metastatic process.
For additional details on the mechanism and pathology of
tumor metastasis, see Isaiah J. Fidler, "Molecular Biology of
Cancer: Invasion and Metastasis," in CANCER: PRIN
CIPLES & PRACTICE OF ONCOLOGY 135-152 (Vincent
T. DeVita et al., editors, 5th ed., 1997).
Accordingly, one aspect of the invention provides meth
ods of using and compositions comprising ligands to
Pgrmcl, which are capable of destabilizing EGFR. A pre
ferred ligand to Pgrmcl is AG-205. These ligands can be
used alone or in combination with other agents or cancer
treatment modalities that prevent metastases or inhibit pro
gression of metastatic lesions.
Another aspect of the invention contemplates the use of
the ligands in combination with other conventional cancer
treatment modalities, in the form of combination therapies.
Many treatments exist for cancers. The particular cancer
therapy or combination of therapy modalities used to treat a
cancer depend greatly on the type of cancer, its stage, the
patient (e.g., weight, sex, age, health, prior cancers, and the
like), and where the patient is in therapy (e.g., first treatment,
in blast crisis, refractive to initial treatments, cancer relapse,
or a second cancer perhaps induced by the treatment of the
first cancer months or years before). Therefore, physicians
will frequently have to combine a variety of treatment
modalities that will best suit the needs of the patient in
combating the disease and the patient's self-determination of
quality of life.
Treatment modalities include but are not limited to sur
gery, radiation therapy, chemotherapy, biologic therapy
(e.g., cytokines, immunotherapy, and interferons), hormone
therapies, and hyperthermia. Conventional chemotherapy
can be further broken down into hormone therapies (e.g.,
antiestrogens, aromatase inhibitors, gonadotropin-releasing
hormone analogues, and anti-androgens), anti-tumor alky
lating agents (e.g., mustards, nitrosoureas, tetrazines, and
aziridines), cisplatin and its analogues, anti-metabolites
(e.g., methotrexate, antifolates, 5-fluoropyrimidines, cytara
bine, azacitidine, gemcitabine, 6-thipurines, and hydroxyu
rea), topoisomerase interactive agents, antimicrotubule
agents (e.g., vinca alkaloids, taxanes, and estramustine),
differentiating agents (e.g., retinoids, vitamin D3, polar
apolar compounds, butyrate and phenylactetate, cytotoxic
drugs, cytokines, and combinations thereof), and other che
motherapeutic agents such as fludarabine, 2-chlorodeoxy
adenosine, 2'-deoxycoformycin, homoharringtonine (HHT),
suramin, bleomycin, and L-asparaginase.
Treatment of metastases may be with the compositions,
combination therapies and methods described herein by
themselves or in combination with other cancer treatment
modalities depending on the site of the metastases and the
primary tumor from which the metastases originates. The
most common sites for tumors to metastasize are brain, lung,
liver, bone, malignant pleural and pericardia! effusions, and
mali gnant ascites.
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The lungs are the second most frequent site of metastatic
disease. Anatomically, the lungs are vascular rich sites and
the first capill ary bed encountered by circulating tumor cells
as they exit from the venous drainage system of their
primary tumor. Thus, the lungs act as the initial filtration site,
where disseminated tumor cells become mechanically
trapped. However, the cells which get trapped there and go
on to proliferate and form metastatic lesions will largely
depend upon the original primary tumor from which they
derive. This hematogenous process of lung metastases is the
most common means, but pulmonary metastases can also
occur via the lymphatic system. See Harvey I. Pass et al.,
"Metastatic Cancer to the Lung," in CANCER: PRIN
CIPLES & PRACTICE OF ONCOLOGY 2536-2551 (Vin
cent T. DeVita et al., editors, 5th ed., 1997). The most
common primary tumors which go on to have lung metas
tases include soft tissue sarcoma, colorectal carcinoma,
germ cell tumors, osteosarcoma, certain pediatric tumors
(e.g., rhabdomyosarcomas, Ewing's sarcomas, Wilm's
tumor, liposarcomas, leiomyosarcomas, alveolar sarcomas,
synovial sarcomas, fibrosarcomas, neurogenic sarcomas,
and epithelial sarcomas), melanoma, renal cell carcinoma,
and breast carcinoma. Most of the metastases from these
primary tumors are treated surgically. However, some recommend surgery in combination with chemotherapy. For
example, germ cell tumors which have metastasized to the
lung are treated with surgical resection following curative
cisplatin-based combination chemotherapy.
Treatment of lung metastases frequently involves metas
tasectomy (i.e., surgical removal of the lung metastatic
lesion). Thus one aspect of the invention contemplates the
use of the disclosed antibodies in combination with conven
tional therapies, as discussed herein or as known in the art,
for the treatment of lung metastases.
Further, the present invention contemplates the use of
ligands to Pgrmcl, able to destabilize a receptor tyrosine
kinase such as EGFR. These ligands of interest preferably
are administered in a physiologically acceptable carrier to a
subject. The ligands may be administered in a variety of
ways including but not limited to parenteral administration,
including subcutaneous (s.c.), subdural, intravenous (i.v.),
intramuscular (i.m.), intrathecal, intraperitoneal (i.p.),
intracerebral, intraarterial, or intralesional routes of admin
istration, localized (e.g., surgical application or surgical
suppository), and pulmonary (e.g., aerosols, inhalation, or
powder) and as described further below. Preferably, the
ligands are administered intravenously or subcutaneously.
Depending upon the manner of introduction, the ligands
may be formulated in various ways. The concentration of
therapeutically active ligand in the formulation (i.e., a for
mulation that is therapeutically effective to the subject to
which it was administered) may vary from about 0.01
mg/mL to 1 g/mL. Preferably, the immunoglobulin compo
sition, when administered to a subject in need thereof,
reaches a concentration in the blood of the subject to whom
it was administered of about 10 µg/mL or more.
Preferably, the ligand is formulated for parenteral admin
istration in a suitable inert carrier, such as a sterile physi
ological saline solution. The dose administered will be
determined by route of administration. Preferred routes of
administration include parenteral, subcutaneous, or intrave
nous administration.
For parenteral administration, the ligands of the invention
can be administered as injectable dosages of a solution or
suspension of the substance in a physiologically acceptable
diluent with a pharmaceutical carrier, which can be a sterile
liquid such as water and oils with or without the addition of
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a surfactant. Other acceptable diluents include oils of ani
mal, vegetable, or synthetic origin, for example, peanut oil,
soybean oil, and mineral oil. In general, glycols such as
propylene glycol or polyethylene glycol (PEG) are preferred
liquid carriers, particularly for injectable solutions. The
ligands can be administered in the form of a depot injection
or implant preparation, which can be formulated in such a
manner as to permit a sustained release of the active ingre
dient(s).
According to one aspect of the invention, the ligand of
interest may be administered alone, or in combination with
other agents as discussed above to treat and/ameliorate a
tumor. These reagents can also be used in the preparation of
a medicament for use in treating a patient. Administration of
other cancer therapeutic agents can occur prior to, concur
rent with, or after administration with the immunoglobulin.
Administration of the subject immunoglobulins can occur
before, during or after surgical treatment, radiotherapy,
hormone therapy, immunotherapy, hyperthermia, or other
cancer treatment modality. Administration of the subject
immunoglobulins can occur daily, weekly, or monthly as
needed. Preferably, the immunoglobulins are administered
weekly for one or more weeks.
Pharmaceutical compositions comprising the ligands can
also include, if desired, pharmaceutically acceptable, nontoxic carriers or diluents, which are vehicles commonly used
to formulate pharmaceutical compositions for animal or
human administration. The diluent is selected so as not to
affect the biological activity of the combination. Examples
include but are not limited to distilled water, physiological
phosphate-buffered saline, Ringer's solutions, dextrose solu
tion, and Hank's solution.
The agents of the invention can be formulated into
preparations for injections by dissolving, suspending or
emulsifying them in an aqueous or non-aqueous solvent,
such as vegetable or other similar oils, synthetic aliphatic
acid glycerides, esters of higher aliphatic acids or propylene
glycol. The formulations may also contain conventional
additives, such as solubilizers, isotonic agents, suspending
agents, emulsifying agents, stabilizers and preservatives.
Suitable examples of sustained-release preparations
include semipermeable matrices of solid hydrophobic poly
mers containing the protein, which matrices are in the form
of shaped articles, e.g., films, or microcapsules. Examples of
sustained-release matrices include polyesters, hydrogels
(e.g., poly(2-hydroxyethyl-methacrylate)) as described by
Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981) and
Langer, Chem. Tech. 12: 98-105 (1982) or poly(vinylalco
hol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of
L-glutamic acid and gamma ethyl-L-glutamate (Sidman et
al., Biopolymers 22: 547-556, 1983), non-degradable ethyl
ene-vinyl acetate (Langer et al., supra), degradable lactic
acid-glycolic acid copolymers such as the LUPRON
DEPOT™ (i.e., injectable microspheres composed of lactic
acid-glycolic acid copolymer and leuprolide acetate), and
poly-D-(-)-3-hydroxybutyric acid (EP 133,988).
Sustained-release compositions also include liposomally
entrapped ligand. Liposomes containing the ligand are pre
pared by methods known per se. See, e.g., Epstein et al.,
Proc. Natl. Acad. Sci. USA 82: 3688-92 (1985); Hwang et
al., Proc. Natl. Acad. Sci. USA 77: 4030-4 (1980); U.S. Pat.
Nos. 4,485,045; 4,544,545; 6,139,869; and 6,027,726. Ordi
narily, the liposomes are of the small (about 200 to about 800
Angstroms), unilamellar type in which the lipid content is
greater than about 30 mole percent (mo!. %) cholesterol; the
selected proportion being adjusted for the optimal ligand
therapy.
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The ligands of this invention can be administered in a
sustained release form, for example a depot injection,
implant preparation, or osmotic pump, which can be formu
lated in such a manner as to permit a sustained release of the
active ingredient. Implants for sustained release formula
tions are well-known in the art. Implants are formulated as
microspheres, slabs, etc. with biodegradable or non-biode
gradable polymers. For example, polymers of lactic acid
and/or glycolic acid form an erodible polymer that are
well-tolerated by the host. The implant is placed in prox
imity of a solid tumor for example, so that the local
concentration of active agent is increased at that site relative
to the rest of the body.
A typical daily dosage might range from about 1 µg/kg to
up to about 200 mg/kg subject weight or more, more
preferably from about 0.01 mg/kg to about 150 mg/kg
subject weight, more preferably from about 0.1 mg/kg to
about 100 mg/kg subject weight, more preferably from
about 1 mg/kg to about 75 mg/kg patient weight (and every
integer value between these values) depending on the factors
mentioned herein. Typically, the clinician will administer
immunoglobulin until a dosage is reached that achieves the
desired effect. The progress of this therapy can be easily
monitored by conventional assays.
Although the present invention has been described in
detail with reference to examples below, it is understood that
various modifications can be made without departing from
the spirit of the invention, and would be readily known to the
skilled artisan.
EXAMPLE 1
EGFR is highly expressed in a variety of tumor types, and
the preliminary data show that EGFR levels are sustained by
Pgrmcl. As a result, Pgrmcl drives cell proliferation, at least
in part via EGFR. Pgrmcl/Hpr6 activates multiple serinethreonine kinases. To test the role of Pgrmcl in membrane
associated signaling, Pgrmcl expression was inhibited by
transfection with two separate siRNA oligonucleotide
duplexes to distinct regions of the PGRMCl coding
sequence. As a control, parallel cultures were transfected
with a control siRNA called sicon.
In MDA-MB-468 cells, which over-express EGFR, trans
fection with siPGR caused a nearly complete inhibition of
EGFR levels. This was reflected in a 28-fold decrease in the
predominant 180 kDa tyrosine phosphorylated band in
MDA-MB-468 cells. As expected, Pgrmcl levels were
almost completely inhibited. The DNA end-binding protein
ku70 was used as a control for equal protein loading because
no ku70 alterations were detected in these experiments.
Pgrmcl did not affect EGFR transcription, because EGFR
transcript levels were unchanged in siPGR-transfected cells,
while Pgrmcl levels decreased.
A second siRNA targeting Pgrmcl (which we will refer to
as siPGR2), attenuated EGFR levels to a lesser extent. Using
the siPGR2 siRNA, the levels of the 180 kDa tyrosine
phosphorylated band were diminished, while ku70 was
unaffected.
EGFR drives proliferation of cancer cells through mul
tiple pathways, and during the sub-culturing of Pgrmcl
inhibited cells, it was immediately evident that the cells had
diminished proliferation. When cell growth was tested by a
time course, a 36% decrease in proliferation in Pgrmcl
inhibited cells was detected. The decrease in proliferation
was highly significant (P=0.0015 at day 5 and 0.0017 at day
8). In this assay, cells in quadruplicate were counted during
multiple stages of growth and stained viable cells by trypan
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blue. The results are representative of a duplicate assay and
are consistent with multiple observations during sub-culturing.
The change in proliferation rate between sicon and
siPGR-transfected cells was largely blocked with the EGFR
inhibitor AG1478. In this assay, cells were transfected with
siRNA oligonucleotides, split into 96 well culture dishes and
treated with increasing doses of AG1478. Viability was
measured using the MTT assay. The results suggest that
EGFR contributes to the increased growth rate of Pgrmclexpressing cells. The data were generated using MDA-MB468 human breast cancer cells as a model system. The same
phenotype in A549 human lung cancer cells was found,
which showed decreased EGFR expression after treatment
with RNAi to Pgrmcl. In addition, A549 cells demonstrated
decreased growth in soft agar when expressing a stable
shRNA targeting Pgrmcl. Thus, Pgrmcl stabilizesEGFR in
multiple cell lines from more than one tissue of origin and
affects the functional capacity of EGFR.
There are four aromatic ligands for the Arabidopsis
Pgrmcl homologue (Yoshitani et al., 2005), which is highly
conserved with human Pgrmc1 in the heme- I domain (Hand
et al., 2003). The effect of the Pgrmcl ligand called AG-205
on EGFR stability and viability was tested. When MDAMB-468 cells were treated with increasing doses of AG-205,
a 12-50 µM dose induced a 14-fold decrease inEGFR levels.
In contrast, a 12 µM dose of AG-205 increased Pgrmcl
levels 4.8-fold, while doses of 25 and 50 µM decreased
Pgrmcl to nearly undetectable levels. Ku70 levels were not
affected by the AG-205 treatment.
To assure that the results were not unique to the MDA
MB-468 cell line, A549 lung cancer cells were also treated
with increasing doses of AG-205. As for MDA-MB-468
cells, AG-205 de-stabilized EGFR in a dose-dependent
manner, with 20-50 µM AG-205 having the optimal activity.
In contrast, AG-205 had little effect on the stability of the
focal adhesion kinase or the Met receptor tyrosine kinase.
Pgrmcl Ligand Inhibits Cell Growth in Cancer Cells.
A 20 µM dose of AG-205 decreased EGFR levels and
inhibited cancer cell viability. The 20 µM dose induced cell
rounding and a marked loss of viability in both A549 and
MDA-MB-468 cells. The growth inhibitory activity was
dependent on the culture conditions, with AG-205 killing
cells grown in low serum conditions but not 10% serum. The
difference in viability was highly significant under these
conditions (P=0.0006 for MDA-MB-468 cells at a dose of
20 µM AG-205). While AG-205 induced a loss of viability,
we did not detect an increase in cleavage of the polyADP
ribose polymerase (PARP) or caspase 3, suggesting that the
cells were dying via an apoptotic mechanism.
When ligand is abundant under normal culture conditions,
lower doses ofEGFR are sufficient to maintain cell viability.
AG-205 caused a slight increase in viability in MDA-MB468 cells. In MDA-MB-468 cells, EGF treatment induces
apoptosis, and it is likely that, by reducing EGFR levels,
AG-205 limits EGF-induced apoptosis and has a slight
positive effect on viability. The results suggest that inhibit
ing Pgrmcl with the AG-205 ligand causes EGFR to be
de-stabilized, ultimately leading to cell death.
AG-205 kills cancer cells while Pgrmcl RNAi does not.
This is because RNAi is generally not a complete loss of
function, and we were able to detect residual Pgrmcl
transcription following both siRNA and shRNA, although
transcription was greatly attenuated. There may also be
Pgrmcl variants expressed that we were unable to detect.
Secondly, RNAi inhibits only Pgrmcl, while AG-205 may
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inhibit the related Pgrmc2 and Neudesin proteins as well. It
may be that inhibiting each of these proteins cumulatively
results in cell killing.
The Pgrmcl Ligand AG-205 Mis-Localizes EGFR.
The model shows that Pgrmcl binds to Cavl to increase
the transport of RTKs to the cell membrane and increase
their stability within caveolae once localized to the cell
membrane. One prediction of this model is that disrupting
Pgrmcl function will cause RTKs to accumulate in an
intermediate state away from the cell membrane.
To test this model, EGFR was stained by immunofluo
rescence 24 hours after treatment with 20 µM AG-205 in
MDA-MB-468 cells. In cells treated with the vehicle control, EGFR localized to the cell membrane. In contrast,
EGFR localized to both the cell membrane and an intracel
lular ring which corresponds to the perinuclear region of the
cell. Also, Pgrmcl may control the uptake from the mem
brane to the perinuclear region.
Thus, a mechanism has been found by which cancer cells
stabilize RTKs and promote proliferation. This pathway is
unusual in that the initiating protein is readily targeted by
known ligands, and these ligands cause RTKs to be mis
localized initially, subsequently leading to cell death.
Methodology for the Experiments
Tissue culture. MDA-MB-468 cells were a kind gift from
Dr. Rina Plattner of the University of Kentucky and were
maintained in medium consisting of Dulbecco's Modified
Eagle Medium containing 10% serum supreme (Fisher) and
antibiotics. Cells were grown at 37° C. in 5% C02 in air.
A549 and HCC827 lung cancer cells, as well as SK-Br-3
breast cancer cells were obtained from the ATCC (American
Type Culture Collection) and were grown under the same
conditions. The H1650 lung cancer cell line was a kind gift
from Dr. Heinz Kohler of the University of Kentucky. The
Pgrmcl ligand AG-205 was purchased from Timtec, Inc.
The EGFR inhibitor AG1478 was from Biomol, Inc. and
was used at a concentration range of 0.8-40 µM.
RNAi. For shRNA inhibition, the plasmids pGIPZ and
V2LHS_90636, which is based on pGIPZ and drives the
expression of an shRNA targeting Pgrmcl, were obtained
from Open Biosystems, Inc. and purified using a Qiagen
Maxi-prep purification kit. Viral vectors were produced by
the Viral Vector Core at the Translational Core Laboratories,
Cincinnati Children's Hospital Research Foundation, Cin
cinnati, Ohio. For lentiviral infection, cells were split to a
density of 500,000 cells/100 cm dish, allowed to attach
overnight, and then were switched to medium containing
0.1% serum and infected with 6.4xl05 lentiviral particles in
8 µg/ml polybrene (Chemicon, Inc.) overnight. The cells
were then washed in fresh media, selected in 5 µg/ml
puromycin for 5 days and checked for green fluorescence
microscopically.
Gene inhibition with siRNA transfected using Oligo
fectamine (Invitrogen) was performed essentially as
described (Crudden et al., (2006) J Pharmacol Exp Ther
316:448-55; Mallory et al., (2005) Mo! Pharmacol 68: 174756). To target Pgrmcl, an oligonucleotide duplex corre
sponding to the 21 base pairs after position 509 in the
Pgrmc1 open reading frame was used. The duplex is referred
to as siPGR (Ambion, cat#16706, part#4392421). A second
oligonucleotide duplex targeted a 21 base sequence at posi
tion 559 in the Pgrmcl open reading frame and is referred
to as "siPGR2". The control was the "control silencer #1"
(Ambion, cat#AM4635).
Immunological techniques. Cells were extracted in RIPA
buffer (50 mM Tris, pH 8.0, 1% Nonidet P-40, 150 mM
NaCl, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
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sulfate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml of
aprotinin, leupeptin and pepstatin) for standard western
blotting. The antibodies used in the study were anti-caveo
lin-1 (N-20, Santa Cruz Biologicals, # sc-894), anti-EGFR
(1005, Santa Cruz, # sc-03), anti-ku70 (A-9, Santa Cruz #
sc-5309), anti-Met (C-12, Santa Cruz # sc-10), anti-PARP
(H-250, Santa Cruz # sc-7150), anti-phosphotyrosine
(P-Tyr-100, Cell Signaling), anti-P grmcl (Novus Biologics)
and anti-tubulin (Neomarkers). Some western blots for
Pgrmcl were performed with a polyclonal antibody called
anti-PGR-UKl which was raised in rabbits to an internal 10
amino acid peptide.
For immuno-precipitation, cells were plated at a density
of 500,000 cells/dish in normal growth medium and left
overnight. The next day, the cells were then scraped from the
dish, washed in PBS and lysed in 1% NP-40 buffer (1%
NP-40, 20 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM
Na3V04, pH 7.4, and 10 µg/ml of the protease inhibitors
aprotinin and leupeptin) containing 1 mM Na3V04. The
lysates were divided into equal portions and immune-pre
cipitated with protein A/G-agarose and various antibodies.
After a 3 hour incubation, the agarose was pelleted by
centrifugation and washed three times in 1% NP-40 buffer.
Immunofluorescence for EGFR was performed as
described previously (Crudden et al., (2005) Tumour Biol
26:142-6). Cells were grown on chamber slides, washed and
fixed with 3.7% formaldehyde. The cells were then permea
bilized with 0.1% Triton X-100 in phosphate-buffered
saline, blocked with 10% serum and incubated, in turn, with
anti-EGFR 1005 and a Texas red-labeled anti-rabbit second
ary antibody.
Proliferation, anchorage-independent growth and migra
tion assays. For growth curves, cells were plated in 24 well
dishes and grown in 10% serum-containing medium. At
various times, the cells were harvested with trypsin and fixed
with formaldehyde added to a final concentration of 3.7%.
Following the harvest of the final time point, the cells from
each time point were counted using a Bright-line hemocy
tometer (Hausser Scientific).
MTT viability assays were performed as described pre
viously. Briefly, cells were plated in 96-well tissue culture
dishes and grown in various media with different drug doses.
The cells were then incubated with 0.5 mg/ml of 3-[4,5dimethylthiazol-2-y]-2,5-diphenyltetrazolium bromide for
1.5 hours, at which time the media was removed, the
precipitated crystals were dissolved in dimethyl sulfoxide,
and the absorbance at 590 nm was measured using a Bio-Tek
µQuant spectrophotometer.
FACS was performed essentially as described previously
(Mallory (2005)). Cells were trypsinized, washed and fixed
in 70% ethanol, then stained in 20 µg/ml propidium iodide
containing 50 µg/ml DNase-free RNase. FACS analysis was
performed at the University of Kentucky flow cytometry
facility, and the data were analyzed using Modfit software
(Verity, Inc.).
For soft agar assays, cells were resuspended in 0.4% agar
in DMEM at a density of 200 cells/ml and overlaid on 1%
agar, which was also dissolved in lxDMEM. Cells were
plated in triplicate, and the assay was performed at least two
separate times. Cells were grown for approximately 2 weeks
and imaged using an Olympus IX70 microscope. The perim
eters of 30-35 different colonies were calculated using
Pictureframe 2.3 software (Optronics, Inc.).
To assay migration, serum-starved shRNA-expressing
cells were suspended in DMEM containing 1% bovine
serum albumin and placed in the top well of invasion
chambers (BD Biosciences). Medium containing 10% serum
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was placed in the lower chamber as a chemoattractant. Cells
were allowed to invade for 16 hours at 37 ° C. Cells on the
upper surface of the membrane were removed, and cells on
the undersurface were fixed, stained with 0.5% crystal violet
in 20% methanol and counted.
RT-PCR. Cells were harvested with trypsin, and RNA was
purified, reverse transcribed with random hexamers, and
amplified using Taq polymerase (GenScript, Piscataway,
N.J.) in an Eppendorf Master Cycler (Eppendorf, Westbury,
N.Y.) for 28-34 cycles of 94 ° C. for 1 minute., 55 ° C. for 1
minute., and 72 ° C. for 1 minute. PCR reactions contained
primers to either EGFR, Pgrmcl, LDLR or PAii in combi
nation with primers to actin, which served as an internal
control for cDNA loading. The primer sequences for EGFR
were EGFR+lOOF (ACGAGTAACAAGCTCACGCAG
(SEQ ID NO: 1)) and EGFR+380R (TGCATCATAGTTA
GATAAGAC (SEQ ID NO: 2)); the primers for PAii were
PAI+90F (GTGGCCCACCTGGCCTCAGAC (SEQ ID
NO: 3))and PAI+360R (GATCGCGTCTGTGGTGCTGA
(SEQ ID NO: 4)); and the primers for LDLR were LDLR+
lOOF (TGCCAAGACGGGAAATGCATC (SEQ ID NO: 5))
and LDLR+379R (CGAACTGCCGAGAGATGCAC (SEQ
ID NO: 6)). P grmcl was amplified with the primers HPR+
1080F and HPR+1370R, which have been described previously (Crudden et al., (2006) J Pharmacol Exp Ther 316:
448-55) as have the actin primers (Cance et al., (1992) Surg
Oncol l:309-14). PCR products were visualized by electro
phoresis in 2% agarose 1000 (Invitrogen).
Sucrose gradient fractionation. Caveolae fractionation
was performed essentially as described (Liu et al. (1998)
Biochem Biophys Res Commun 245:684-90). Cells were
washed once with PBS, suspended in Tris lysis buffer (25
mM Tris, pH 7.4, 250 mM sucrose and 2 mM EDTA) and
lysed by dounce homogenization, passage through a 25
gauge needle and three rounds of sonication. Lysates were
then mixed with MBS buffer (25 mM MES, pH 6.5, 150 mM
NaCl and 2 mM EDTA) containing 80% sucrose, mixed and
overlaid in a SW 41 rotor tube with MBS containing 35%
sucrose and 5% sucrose. The gradient was centrifuged for 3
hours at 175,000xg, and 1.2 ml fractions were collected.
Results of the Experiments
Pgrmcl stabilizes EGFR. Pgrmcl/Hpr6 activates multiple
serine-threonine kinases. To test the role of Pgrmcl in
membrane-associated signaling, Pgrmcl expression was
inhibited by transfection with two separate siRNA oligo
nucleotide duplexes to distinct regions of the P grmcl coding
sequence.
In MDA-MB-468 cells, which over-express EGFR, trans
fection with siPGR caused a nearly complete inhibition of
EGFR levels. This was reflected in a 28-fold decrease in the
predominant 180 kDa tyrosine phosphorylated band in
MDA-MB-468 cells. As expected, Pgrmcl levels were
almost completely inhibited. The DNA end-binding protein
ku70 was used as a control for equal protein loading because
no ku70 alterations were detected in these experiments.
P grmcl did not affect EGFR transcription, because EGFR
transcript levels were unchanged in siPGR-transfected cells,
while Pgrmcl levels decreased.
A second siRNA targeting Pgrmcl (which we will refer to
as siPGR2), attenuated EGFR levels to a lesser extent. Using
the siPGR2 siRNA, the levels of the 180 kDa tyrosine
phosphorylated band were diminished, while ku70 was
unaffected.
EGFR drives proliferation of cancer cells through mul
tiple pathways, and we detected a 36% decrease in prolif
eration in Pgrmcl-inhibited cells. The decrease in prolifera
tion was highly significant (P =0.0015 at day 5 and 0.0017 at
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day 8). The change in proliferation rate between siCON and
siPGR-transfected cells was largely blocked with the EGFR
inhibitor AG1478, suggesting that EGFR contributes to the
increased growth rate of Pgrmcl-expressing cells.
Pgrmcl stabilizes EGFR in lung cancer cells. In A549
lung cancer cells, Pgrmcl inhibition by shRNA caused a
4.1-fold reduction in EGFR levels, with no change in Met.
As expected, Pgrmcl levels were inhibited, but tubulin
levels were not. Reduced EGFR levels could arise from
altered transcription or post-transcriptional events. How
ever, EGFR transcript levels were unchanged after Pgrmcl
was inhibited.
The shPGR short hairpin targeted a sequence in the end of
the 3' untranslated region of the Pgrmcl transcript. A549
cells infected with the Lv-shPGR lentivirus were transfected
with either a control plasmid or a plasmid expressing a form
of Pgrmcl that lacked the 3' untranslated region
(Pgrmclll3'). A549 cells transfected with the control plas
mid maintained a low level of EGFR, while EGFR was
elevated in cells expressing Pgrmclll3', which was con
firmed by western blot. Thus, EGFR levels are dependent on
Pgrmcl expression.
EGFR promotes growth and adhesion of lung cancer
cells, and we tested the extent to which these properties were
altered when Pgrmcl was inhibited. A549/GIPZ and A549/
shPGR cells grew at equivalent rates, and we did not detect
any change in their cell cycle profile by FACS analysis. In
contrast, growth in soft agar differed markedly between the
two cell populations. A549/GIPZ cells readily formed colo
nies in soft agar, while A549/shPGR cells formed small
microcolonies that failed to proliferate. The radii of 30
colonies from each cell population were measured, and
A549/GIPZ colonies were 2.9-fold larger, a difference that
was highly significant (P=6xl0-13, t-test). A box plot of the
data in In addition, migration in A549/GIPZ cells was
4.4-fold higher than that of A549/shPGR cells, an effect that
was highly significant (P=0.002, t-test). Thus, Pgrmcl
increases anchorage independent growth and migration.
A Pgrmcl ligand inhibits EGFR stability. There are four
aromatic ligands for the Arabidopsis Pgrmcl homologue,
which is highly conserved with human Pgrmcl in the
heme-I domain. The effect of the Pgrmcl ligand called
AG-205 on EGFR stability and viability was tested. When
MDA-MB-468 cells were treated with increasing doses of
AG-205, a 12-50 µM dose induced a 14-fold decrease in
EGFR levels. In contrast, a 12 µM dose of AG-205 increased
Pgrmcl levels 4.8-fold, while doses of 25 and 50 µM
decreased Pgrmcl to nearly undetectable levels. Ku70 levels
were not affected by the AG-205 treatment. The results were
not specific for MDA-MB-468 cells, because EGFR was
also inhibited by AG-205 in A549 cells, while tyrosine
kinase FAK and ku70 were unaffected.
A 20 µM dose of AG-205 inhibited cancer cell viability
72-96 hours after treatment. The 20 µM dose induced cell
rounding and a marked loss of viability in both MDA-MB468 and A549 cells. The growth inhibitory activity was
dependent on the culture conditions, with AG-205 killing
cells grown in low serum conditions but not 10% serum. The
difference in viability was highly significant under these
conditions (P=0.0006 for MDA-MB-468 cells at a dose of
20 µM AG-205). While AG-205 induced a loss of viability,
we did not detect an increase in cleavage of the poly ADP
ribose polymerase (PARP) or caspase 3, suggesting that the
cells were dying via an apoptotic mechanism.
Because AG-205 inhibited EGFR levels and cell viability,
the extent to which the two effects were related was tested.
A549 cells were treated with the EGFR inhibitor AG-1478,
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alone or in combination with AG-205. AG-1478 induced a
25% decrease in viability, while AG-205 was toxic to 47%
of the cells, and the combination of the two drugs was not
significantly different from that of AG-205 (P=0.31, t-test).
The results support the model that AG-1478 and AG-205
function through a common mechanism, which includes
EGFR. The toxicity of AG-205 is also dependent on Pgrmc1,
because Pgrmcl-inhibited A549 cells exhibited decreased
toxicity to AG-205 (P=0.0001, t-test). This experiment was
analyzed after 36 hours, and after a longer incubation, both
cell types exhibited loss of viability.
Structural features of EGFR appear to be important for the
growth inhibiting activity of AG-205. In A549 and MDA
MB-468 cells, AG-205 efficiently inhibited cell growth, and
both cell lines express the wild-type form of EGFR (Table
1). NIH-3T3 cells also express the wild-type EGFR and
were inhibited by AG-205 (Table 1). In contrast, HCC827
and H1650 cells, which express a llE746-A750 deletion
mutant of EGFR, were relatively insensitive to AG-205
inhibition (Table 1). SK-Br-3 cells, which express modest
amounts of EGFR but extremely high levels of HER2/neu,
were also relatively insensitive to AG-205 (Table 1). The
results suggest that, in the cell lines tested, alterations in
EGFR activation or binding partners can overcome AG-205
sensitivity.
The model is that high EGFR expression is required for
maintaining viability under low serum conditions, perhaps
via paracrine signaling. When ligand is abundant under
normal culture conditions, lower doses of EGFR are suffi
cient to maintain cell viability. Interestingly, AG-205 caused
a slight increase in viability in MDA-MB-468 cells. In
MDA-MB-468 cells, EGF treatment induces apoptosis
(Armstrong et al., (1994) Cancer Res 54:5280-3), and it is
likely that, by reducing EGFR levels, AG-205 limits EGF
induced apoptosis and has a slight positive effect on viabil
ity.
Pgrmcl maintains EGFR at the cell membrane, and the
localization of EGFR in AG-205-treated cells after 24 hours
was tested. Surprisingly, EGFR localized to the perinuclear
region of the cell, similar to its localization after RNAi
inhibition.
TABLE I
IC50 values for AG-205 in various cell lines

50

Cell line

A431
MDA-MB-231
MDA-MB-468
55 A549
H157
H358
H1650
HCC827

Tissue of origin
epitheloid
breast
breast
lung
lung
lung
lung
lung

Serum-starved (µM) EGFR
18
12
15
10
12
>100
>100

wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
L\.E746-A750
L\.E746-A750

60

65

It will be appreciated that, although specific embodiments
of the invention have been described herein for purp oses of
illustration, various modifications may be made without
departing from the spirit and the scope of the invention.
Accordingly, the invention is not limited except as by the
appended claims.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS, 8
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 1
acgagtaaca agctcacgca g
<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 2
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 2
tgcatcatag ttagataaga c
<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 3
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 3
gtggcccacc tggcctcaga c
<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 4
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 4
gatcgcgtct gtggtgctga
<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 5
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 5
tgccaagacg ggaaatgcat c
<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 6
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE,
cgaactgccg agagatgcac

20

25
<210>
<211>
<212>
<213>
<220>
<223>
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-continued

SEQ ID NO 7
LENGTH, 54
TYPE, PRT
ORGA NISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polypeptide

<400> SEQUENCE, 7
Ala Ile Asn Gly Lys Val Phe Asp Val Thr Lys Gly Arg Lys Phe Tyr
1
5
10
15
Gly Pro Glu Gly Pro Tyr Gly Val Phe Ala Gly Arg Asp Ala Ser Arg
20
25
30
Gly Leu Thr Leu Ser Asp Trp Glu Ser Gln Phe Thr Phe Lys Tyr His
35
40
45
His Val Gly Lys Leu Leu
50
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH, 54
TYPE, PRT
ORGA NISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polypeptide

<400> SEQUENCE, 8
Ala Ile Lys Gly Arg Val Phe Asp Val Thr Thr Gly Lys Ser Phe Tyr
1
5
10
15
Gly Ser Gly Gly Asp Tyr Ser Met Phe Ala Gly Lys Asp Ala Ser Arg
20
25
30
Ala Leu Thr Leu Asn Asp Trp Glu Thr Lys Phe Glu Ala Lys Tyr Pro
35
40
45
Val Val Gly Arg Val Val
50

What is claimed is:
1. A method for inhibiting growth of a tumor and/or
metastatic progression thereof in a human subject in need
thereof comprising administering a compound named
AG-205 consisting of the following formula

40

45

l;k-o-c,
S

50

3. The method of claim 1, wherein the subject is admin
isteredAG-205 in an amount of0.1 mg/kg subject weight to
100 mg/kg subject weight.
4. The method of claim 1, wherein the metastatic progression is to brain, lung, liver, or bone.
5. A method for inhibiting growth of a tumor and/or
metastatic progression thereof in a human subject in need
thereof comprising administering a compound named
AG-205 consisting_of the following formula

N�
0
55

to the human subject in need thereof in an amount
sufficient to inhibit growth of the tumor and/or meta
60
static progression thereof,
wherein the tumor comprises breast cancer cells over
expressing progesterone receptor membrane compo
to the human subject in need thereof in an amount sufficient
nent-I and wild type epidermal growth factor receptor,
to inhibit growth of the tumor and/or metastatic progression
wherein AG-205 destabilizes the epidermal growth
factor receptor.
65 thereof, administering a chemotherapeutic agent, and further
2. The method of claim 1, wherein the tumor is a primary
administering an immunotherapeutic agent and/or radiation
tumor or a metastatic lesion.
therapy, wherein the tumor comprises breast cancer cells
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over-expressing progesterone receptor membrane compo
nent-I and wild type epidermal growth factor receptor, and
wherein the AG-205 destabilizes the epidermal growth fac
tor receptor.
6. The method of claim 5, wherein AG-205 is adminis- 5
tered intravenously, intrathecally, or subcutaneously to the
subject in need thereof.
7. The method of claim 5, wherein AG-205 is adminis
tered in an amount of 1 mg/kg subject weight to 100 mg/kg
subject weight.
10
8. The method of claim 5, wherein AG-205 is adminis
tered daily, weekly, or monthly.

* * * * *
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